Welcome to our dedicated page for Spectral AI news (Ticker: MDAIW), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Spectral AI, Inc. (Nasdaq: MDAIW for its redeemable warrants) is a Dallas-based predictive AI company focused on medical diagnostics in wound care, with initial applications in burn treatment. Company news updates center on the development, clinical use, and regulatory progress of its DeepView System, a non-invasive device and software platform that combines multispectral imaging with proprietary AI algorithms to assess burn wound healing potential.
News coverage for Spectral AI frequently includes announcements about the DeepView System’s role at major burn conferences, such as the British Burn Association, European Burns Association, and regional U.S. burn meetings. These reports describe presentations and posters on topics like AI-enhanced multispectral imaging, real-world burn healing studies, reader studies evaluating clinicians’ ability to detect non-healing wounds, and patient experience with AI-based imaging in burn consultations.
Investors and healthcare professionals can also find updates on Spectral AI’s financial results, including research and development revenue tied to its BARDA Project BioShield contract, cash position, and financing activities that support ongoing DeepView development. Regulatory milestones, such as the submission of a De Novo 510(k) marketing clearance application to the U.S. Food and Drug Administration for DeepView’s use in burn care settings, are another recurring theme in the company’s news releases.
By following Spectral AI news, readers can track how the company reports progress on its AI-driven DeepView technology, its participation in clinical and professional forums, and its efforts to position DeepView as a predictive diagnostic tool in burn and wound care.
Spectral AI (Nasdaq: MDAI) reported Q4 2025 R&D revenue $3.8M and FY 2025 R&D revenue $19.7M. Cash was $15.4M at December 31, 2025, and Q4 net income was $0.6M while FY net loss was $(7.6M). The company submitted a De Novo 510(k) for DeepView burn indication and received $31.7M additional BARDA funding, with $54.9M committed to date under a contract valued up to $150M. Spectral AI provided 2026 revenue guidance of approximately $18.5M.
Spectral AI (Nasdaq: MDAI) received $31.7 million from BARDA to accelerate feature development of its DeepView® System, an AI burn wound imaging platform. The company will add $9.7 million toward development; BARDA funding supplements $54.9 million previously committed under a contract valued up to $150.0 million. The award is non-dilutive as Spectral AI awaits a determination on market authorization from the U.S. FDA for DeepView.
Spectral AI (Nasdaq: MDAI) will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026 after market close. A conference call to discuss results will be held the same day at 5:00 PM ET. Investors may dial in or join a simultaneous webcast via the company investor events page.
Dial-in: 833-890-6620 (U.S.), 412-564-3789 (International). Webcast available at the company’s Investor Relations Events page.
Spectral AI (Nasdaq: MDAI) appointed Vincent S. Capone as Chief Executive Officer effective February 9, 2026, promoting its CFO and general counsel as the company shifts toward commercialization of its DeepView® non-invasive, AI-driven burn wound assessment device.
The company highlighted its June 2025 FDA submission as a major milestone and said the leadership change will support commercial execution with the chairman remaining as executive chairman.
Spectral AI (Nasdaq: MDAI) will participate in National Burn Awareness Week, Feb 1–7, 2026, partnering with the American Burn Association to promote workplace burn prevention and employee education.
The company highlighted internal events, leadership messages, engineer stories, and burn-safety tips, and referenced its June 2025 De Novo submission to the FDA for the DeepView System.
Spectral AI (Nasdaq: MDAI) showcased its DeepView System at the Southern Region Burn Conference in Charleston (Oct 30–Nov 2, 2025) and will be highlighted at the Northeast Region Burn Conference in Washington, DC (Nov 21–22, 2025).
The DeepView System was featured in sessions on initial cost savings, AI training methodology, and clinician decision accuracy under a “wait-and-see” approach. Company leaders and clinicians emphasized evidence-based burn assessment and physician collaboration to improve patient outcomes and introduce the technology to the market.
Spectral AI (NASDAQ: MDAI) reported third-quarter 2025 results for the period ended September 30, 2025, highlighting Q3 R&D revenue of $3.8 million and YTD revenue of $15.6 million. Cash improved to $10.5 million as of Sept 30, 2025 (flat vs Q2 2025; up from $3.7M in Q3 2024). The company recorded a Q3 net loss of $3.6 million versus $1.5 million a year earlier, driven by a 54% decline in R&D revenue after its June De Novo submission to the FDA.
After quarter close (Oct 22, 2025) Spectral entered a securities purchase agreement raising ~$7.6 million gross via common shares, warrants and pre-funded warrants. Full-year revenue guidance was lowered from $21.5M to $18.5M, citing BARDA timing and a U.S. government shutdown impact.
Spectral AI (Nasdaq: MDAI) will report third quarter financial results for the period ended September 30, 2025 on Tuesday, November 11, 2025 after market close. The company will host a conference call the same day at 5:00 PM ET to discuss results. Investors can join by dialing 833-630-1956 (U.S.) or 412-317-1837 (International), or via a simultaneous webcast available on the company’s Investor Relations Events & Presentations page at https://investors.spectral-ai.com/news-events/events.
Spectral AI (Nasdaq: MDAI) priced a $7.6 million offering on October 23, 2025 to fund expansion of its DeepView® System. The financing includes the issuance of 4,000,000 shares of common stock and pre-funded warrants at $1.90 per share, plus corresponding warrants with an exercise price of $2.51 per share.
The company said proceeds will support continued development, broaden clinical indications, and prepare for commercial readiness in 2026, while maintaining support for its BARDA Project BioShield contract. Northland Capital Markets served as exclusive placement agent and Reed Smith served as counsel.
Spectral AI (Nasdaq: MDAI), a medical diagnostics company specializing in AI-powered wound care solutions, has been recognized on TIME's World's Top HealthTech Companies 2025 list. The prestigious ranking, published on September 18, 2025, features 400 leading healthcare technology innovators selected from thousands of companies globally.
Companies were evaluated based on three key criteria: financial performance, reputation analysis, and online engagement. The recognition highlights Spectral AI's progress in developing their DeepView technology as they work towards global commercialization of their AI-based predictive wound care solutions.